DE:MVR0 Stock Latest News
Company AnnouncementsMedivir Updates Share Structure Following LTIP 2023 Conversion1M ago
Company AnnouncementsMedivir Bolsters Finances as Fostrox and MIV-711 Advance in Key Phase II Programs2M ago
Company AnnouncementsMedivir Expands Share Capital to Fund MIV-711 Orphan Indication3M ago
Company AnnouncementsMedivir Shareholders Approve Directed Issue to Bolster Drug Development3M ago
Company AnnouncementsMedivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination3M ago
Company AnnouncementsMedivir Expands Share Capital Following First Tranche of Directed Issue4M ago
Company AnnouncementsMedivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm4M ago
- Company AnnouncementsMedivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease4M ago
- Company AnnouncementsMedivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug4M ago
- Company AnnouncementsMedivir’s fostrox combo shows promising liver cancer data in key journal4M ago
- Company AnnouncementsMedivir Begins Key Phase 2 Trial of Fostrox Combo in Advanced Liver Cancer5M ago
Company AnnouncementsMedivir AGM Backs Board, Extends Capital Mandate and Adopts New Incentive Plan5M ago
Company AnnouncementsMedivir Strengthens Finances and Pipeline as Key Cancer and Bone Programs Advance6M ago
Company AnnouncementsMedivir targets Asian partnerships as it showcases liver cancer and bone disease drugs6M ago
- Company AnnouncementsMedivir Delays Q1 Report as South Korea Liver Cancer Trial Expands6M ago
- Company AnnouncementsMedivir Calls 2026 AGM, Details Shareholder Voting Procedures and Capital Structure6M ago
Company AnnouncementsMedivir sharpens focus on late-stage liver cancer and rare bone disease programs7M ago
Company AnnouncementsMedivir forms elite expert council to drive MIV-711 push in brittle bone disease7M ago
Company AnnouncementsMedivir to Showcase Phase 2 Advances for Key Cancer and Bone Disease Programs8M ago